Atea Pharmaceuticals, Inc.(AVIR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AVIR Atea Pharmaceuticals, Inc.

盘后交易 08-10 17:46:05 EDT

5.02

-0.23

-4.38%

盘后4.92

-0.10-1.99%

16:52 EDT

最高5.29	最低5.01	成交量12.36万
今开5.21	昨收5.25	日振幅5.33%
总市值4.00亿	流通市值3.01亿	总股本7,967万
成交额62.47万	换手率0.21%	流通股本6,005万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AVIR","market":"US","secType":"STK","nameCN":"Atea Pharmaceuticals, Inc.","latestPrice":5.02,"timestamp":1786392000000,"preClose":5.25,"halted":0,"volume":123550,"hourTrading":{"tag":"盘后","latestPrice":4.92,"preClose":5.02,"latestTime":"16:52 EDT","volume":5786,"amount":28999.2202324,"timestamp":1786395151629,"change":-0.1,"changeRate":-0.01992,"amplitude":0.01992},"delay":0,"changeRate":-0.04380952380952389,"floatShares":60052299,"shares":79672083,"eps":-2.118827,"marketStatus":"盘后交易","change":-0.23,"latestTime":"08-10 17:46:05 EDT","open":5.21,"high":5.29,"low":5.01,"amount":624729.2777249999,"amplitude":0.053333,"askPrice":5.02,"askSize":175,"bidPrice":4.92,"bidSize":325,"shortable":3,"etf":0,"ttmEps":-2.118827,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1786406400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1604030400000,"exchange":"NASDAQ","adjPreClose":5.25,"preHourTrading":{"tag":"盘前","latestPrice":5.26,"preClose":5.25,"latestTime":"08:17 EDT","volume":50,"amount":263,"timestamp":1786364229089,"change":0.01,"changeRate":0.001905,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.92,"preClose":5.02,"latestTime":"16:52 EDT","volume":5786,"amount":28999.2202324,"timestamp":1786395151629,"change":-0.1,"changeRate":-0.01992,"amplitude":0.01992},"volumeRatio":0.439465,"impliedVol":1.5852,"impliedVolPercentile":0.6972},"requestUrl":"/m/hq/s/AVIR","defaultTab":"news","newsList":[{"id":"1125059545","title":"Atea Pharmaceuticals 公布C-Beyond试验：Bem/Rzr 在3期临床试验中总体安全，未见药物相关严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1125059545","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125059545?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:11","pubTimestamp":1785237103,"startTime":"0","endTime":"0","summary":"Atea Pharmaceuticals 宣布，在其C-Beyond研究项目中，Bem/Rzr 组合疗法总体安全性良好。 最关键的是，在3期临床试验过程中，并未出现任何与药物相关的严重不良事件。 这一结果，无疑为这款候选药物的后续开发注入了新的信心。 安全性的初步验证，是迈向更广阔临床应用的关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVIR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134861533","title":"Atea Pharmaceuticals三期北美C-Beyond试验达标：Bemnifosbuvir/Ruzasvir针对丙肝病毒的主要与次要终点均获成功","url":"https://stock-news.laohu8.com/highlight/detail?id=1134861533","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134861533?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:02","pubTimestamp":1785236532,"startTime":"0","endTime":"0","summary":"Atea Pharmaceuticals在北美地区开展的C-Beyond三期临床试验中，就Bemnifosbuvir/Ruzasvir联合疗法用于丙型肝炎病毒的治疗，成功实现了主要终点与次要终点的双项达标。这一里程碑式的成果，标志着该药物组合在关键疗效指标上展现了显著优势。试验结果不仅验证了其核心治疗效力，更在次要评估维度中同样取得了令人瞩目的突破，为丙肝患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AVIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156875546","title":"Atea Pharmaceuticals启动AT-587治疗戊型肝炎的首个人体一期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1156875546","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156875546?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:02","pubTimestamp":1784026942,"startTime":"0","endTime":"0","summary":"Atea Pharmaceuticals公司已正式启动其候选药物AT-587用于治疗戊型肝炎病毒（HEV）感染的首个人体一期临床试验。这项研究标志着该药物研发进程中的一个重要里程碑，旨在初步评估其在人体中的安全性、耐受性及药代动力学特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AVIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129149043","title":"Atea制药完成评估Bemnifosbuvir与Ruzasvir治疗丙型肝炎的3期C-forward试验患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1129149043","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129149043?lang=zh_cn&edition=full","pubTime":"2026-06-25 19:02","pubTimestamp":1782385351,"startTime":"0","endTime":"0","summary":"Atea制药公司宣布，其评估Bemnifosbuvir与Ruzasvir联合疗法用于治疗丙型肝炎病毒的3期C-forward临床试验，已完成患者招募工作。这项关键性研究的推进，标志着该潜在治疗方案向监管提交迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVIR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188919468","title":"Atea制药公司：20毫克奥美拉唑不影响Bem/Rzr血浆暴露量；40毫克轻微降低暴露量","url":"https://stock-news.laohu8.com/highlight/detail?id=1188919468","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188919468?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:10","pubTimestamp":1779880233,"startTime":"0","endTime":"0","summary":"Atea制药公司公布的研究数据显示，在药物相互作用研究中，20毫克剂量的奥美拉唑并未对Bem/Rzr的血浆暴露量产生显著影响。然而，当奥美拉唑剂量提升至40毫克时，观察到Bem/Rzr的血浆暴露量出现轻微下降。这一发现对于评估Bem/Rzr与常用胃酸抑制剂的联合用药安全性具有参考价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVIR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192114080","title":"Atea制药公司一期试验显示：无论是否联用奥美拉唑，Bem/Rzr均安全且耐受性良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1192114080","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192114080?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:09","pubTimestamp":1779880173,"startTime":"0","endTime":"0","summary":"Atea制药公司公布的一项一期临床试验结果显示，其研究性药物Bem/Rzr在单独使用或与奥美拉唑联合使用时，均表现出良好的安全性和耐受性特征。该数据为后续开发提供了重要支持，表明该药物组合方案具有进一步研究的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVIR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113465436","title":"Atea制药在2026年欧洲肝病学会大会上公布支持Bemnifosbuvir与Ruzasvir联合疗法治疗丙型肝炎病毒具备潜在最佳疗效特征的新药-药相互作用结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1113465436","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113465436?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:01","pubTimestamp":1779879696,"startTime":"0","endTime":"0","summary":"Atea制药公司在2026年欧洲肝病学会大会上公布了新的药物相互作用研究结果。这些数据有力支持了其Bemnifosbuvir与Ruzasvir联合疗法在治疗丙型肝炎病毒方面具备潜在的同类最佳特征。该联合用药方案旨在为患者提供高效且安全的治疗选择，新揭示的药物相互作用特性进一步巩固了其作为潜在领先疗法的地位，有望为丙肝治疗领域带来新的突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AVIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166601867","title":"Atea Pharmaceuticals在Croi 2026公布临床前结果，支持首创药物AT-587治疗戊型肝炎病毒的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1166601867","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166601867?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:05","pubTimestamp":1771934752,"startTime":"0","endTime":"0","summary":"Atea Pharmaceuticals, Inc. (简称：Atea) 在近期举行的Croi 2026会议上，公布了其候选药物AT-587针对戊型肝炎病毒(HEV)的临床前研究数据。这些结果充分展示了AT-587作为同类首创疗法的巨大潜力。\n临床前研究数据显示，AT-587在体外和体内模型中均表现出强大的抗病毒活性，能有效抑制HEV的复制。该药物通过一种新颖的作用机制靶向病毒，为其作为潜在的一线治疗方案提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AVIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518281053","title":"Atea Pharmaceuticals, Inc.2024财年实现净利润-1.68亿美元，同比减少23.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518281053","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518281053?lang=zh_cn&edition=full","pubTime":"2025-03-10 00:01","pubTimestamp":1741536076,"startTime":"0","endTime":"0","summary":"3月10日，Atea Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-1.68亿美元，同比减少23.53%；其中营业收入为0.00美元，每股基本收益为-2.00美元。机构评级：截至2025年3月10日，当前有1家机构对Atea Pharmaceuticals, Inc.目标价做出预测，其中目标均价为6.20美元，其中最低目标价为6.20美元，最高目标价为6.20美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000238a268987a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000238a268987a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144965686","title":"Atea Pharmaceuticals公司第四季度每股亏损0.40美元，未达到预期的每股亏损0.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144965686","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144965686?lang=zh_cn&edition=full","pubTime":"2025-03-07 05:19","pubTimestamp":1741295973,"startTime":"0","endTime":"0","summary":"Atea Pharmaceuticals  公布的季度每股亏损为0.40美元，未达到分析师普遍预计的每股亏损0.37美元，差8.11%。相比去年同期的每股亏损0.47美元，这一亏损减少了14.89%。以上内容来自Benzinga Earnings专栏，原文如下：Atea Pharmaceuticals  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 8.11 percent. This is a 14.89 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Atea Pharmaceuticals公司第四季度每股亏损0.40美元，未达到预期的每股亏损0.37美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509253138","title":"Atea Pharmaceuticals, Inc.盘中异动 股价大涨5.05%报3.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509253138","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509253138?lang=zh_cn&edition=full","pubTime":"2025-02-06 03:31","pubTimestamp":1738783883,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日03时31分，Atea Pharmaceuticals, Inc.股票出现波动，股价快速拉升5.05%。Atea Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为2.41%。其相关个股中，Invivyd, Inc.、Transcode Therapeutics, Inc.、Pasithea Therapeutics Corp.涨幅较大，Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃，换手率分别为4636.38%、2352.41%、1754.62%，振幅较大的相关个股有Oragenics Inc.、Transcode Therapeutics, Inc.、Invivyd, Inc.，振幅分别为132.24%、99.51%、69.59%。Atea Pharmaceuticals, Inc.公司简介：Atea Pharmaceuticals Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化抗病毒疗法，以改善患有严重病毒感染的患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206033124a23ab96d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206033124a23ab96d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVIR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2500149497","title":"Atea Pharmaceuticals, Inc.盘中异动 大幅拉升5.12%报3.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500149497","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2500149497?lang=zh_cn&edition=full","pubTime":"2025-01-04 01:03","pubTimestamp":1735923780,"startTime":"0","endTime":"0","summary":"北京时间2025年01月04日01时03分，Atea Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.12%。Atea Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.70%。Atea Pharmaceuticals, Inc.公司简介：Atea Pharmaceuticals Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化抗病毒疗法，以改善患有严重病毒感染的患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250104010300985a55bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250104010300985a55bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVIR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2500971389","title":"Atea Pharmaceuticals, Inc.盘中异动 早盘快速上涨5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2500971389","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2500971389?lang=zh_cn&edition=full","pubTime":"2025-01-03 00:14","pubTimestamp":1735834476,"startTime":"0","endTime":"0","summary":"北京时间2025年01月03日00时14分，Atea Pharmaceuticals, Inc.股票出现波动，股价大幅上涨5.37%。Atea Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.79%。Atea Pharmaceuticals, Inc.公司简介：Atea Pharmaceuticals Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化抗病毒疗法，以改善患有严重病毒感染的患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103001436985912f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103001436985912f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","AVIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2493426281","title":"Atea Pharmaceuticals, Inc.盘中异动 股价大涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2493426281","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2493426281?lang=zh_cn&edition=full","pubTime":"2024-12-21 00:50","pubTimestamp":1734713422,"startTime":"0","endTime":"0","summary":"北京时间2024年12月21日00时50分，Atea Pharmaceuticals, Inc.股票出现波动，股价快速拉升5.11%。Atea Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.63%。Atea Pharmaceuticals, Inc.公司简介：Atea Pharmaceuticals Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化抗病毒疗法，以改善患有严重病毒感染的患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221005022984cfe97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221005022984cfe97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","AVIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2491692122","title":"Atea Pharmaceuticals, Inc.盘中异动 股价大涨9.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491692122","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2491692122?lang=zh_cn&edition=full","pubTime":"2024-12-16 22:31","pubTimestamp":1734359486,"startTime":"0","endTime":"0","summary":"北京时间2024年12月16日22时31分，Atea Pharmaceuticals, Inc.股票出现异动，股价急速上涨9.22%。Atea Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。Atea Pharmaceuticals, Inc.公司简介：Atea Pharmaceuticals Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化抗病毒疗法，以改善患有严重病毒感染的患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216223126a1f3428c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216223126a1f3428c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVIR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2490042519","title":"Atea Pharmaceuticals, Inc.盘中异动 股价大跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490042519","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2490042519?lang=zh_cn&edition=full","pubTime":"2024-12-11 02:25","pubTimestamp":1733855133,"startTime":"0","endTime":"0","summary":"北京时间2024年12月11日02时25分，Atea Pharmaceuticals, Inc.股票出现波动，股价大幅下跌5.30%。Atea Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.92%。Atea Pharmaceuticals, Inc.公司简介：Atea Pharmaceuticals Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化抗病毒疗法，以改善患有严重病毒感染的患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211022533a1e3fb75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211022533a1e3fb75&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVIR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2489468852","title":"Atea Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.14%报2.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489468852","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2489468852?lang=zh_cn&edition=full","pubTime":"2024-12-05 22:38","pubTimestamp":1733409511,"startTime":"0","endTime":"0","summary":"北京时间2024年12月05日22时38分，Atea Pharmaceuticals, Inc.股票出现波动，股价急速下跌5.14%。截至发稿，该股报2.96美元/股，成交量2.6289万股，换手率0.03%，振幅4.82%。Atea Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。Atea Pharmaceuticals, Inc.公司简介：Atea Pharmaceuticals Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化抗病毒疗法，以改善患有严重病毒感染的患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205223831a1d69d5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205223831a1d69d5f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVIR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2488190863","title":"Atea Pharmaceuticals, Inc.盘中异动 早盘急速下跌5.17%报3.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488190863","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2488190863?lang=zh_cn&edition=full","pubTime":"2024-12-04 22:57","pubTimestamp":1733324277,"startTime":"0","endTime":"0","summary":"北京时间2024年12月04日22时57分，Atea Pharmaceuticals, Inc.股票出现波动，股价大幅跳水5.17%。Atea Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.04%。Atea Pharmaceuticals, Inc.公司简介：Atea Pharmaceuticals Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化抗病毒疗法，以改善患有严重病毒感染的患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204225757971ba1f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204225757971ba1f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVIR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2484548975","title":"Atea Pharmaceuticals, Inc.2024财年第三财季实现净利润-31.15百万美元，同比增加6.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484548975","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2484548975?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:04","pubTimestamp":1731773092,"startTime":"0","endTime":"0","summary":"11月17日，Atea Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第三财季净利润为-31.15百万美元，同比增加6.00%；其中营业收入为0.00美元，每股基本收益为-0.37美元。机构评级：截至2024年11月17日，当前有1家机构对Atea Pharmaceuticals, Inc.目标价做出预测，其中目标均价为6.20美元，其中最低目标价为6.20美元，最高目标价为6.20美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000621a23e0832&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000621a23e0832&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2481984476","title":"Atea Pharmaceuticals, Inc.盘中异动 急速拉升5.06%报3.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481984476","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2481984476?lang=zh_cn&edition=full","pubTime":"2024-11-06 23:21","pubTimestamp":1730906482,"startTime":"0","endTime":"0","summary":"北京时间2024年11月06日23时21分，Atea Pharmaceuticals, Inc.股票出现波动，股价大幅上涨5.06%。Atea Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.45%。Atea Pharmaceuticals, Inc.公司简介：Atea Pharmaceuticals Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化抗病毒疗法，以改善患有严重病毒感染的患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110623212298e40ed4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110623212298e40ed4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVIR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ateapharma.com","stockEarnings":[{"period":"1week","weight":0.117},{"period":"1month","weight":0.0915},{"period":"3month","weight":-0.0331},{"period":"6month","weight":0.2651},{"period":"1year","weight":0.5173},{"period":"ytd","weight":0.4706}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1197},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.1339}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Atea Pharmaceuticals, Inc.于2012年7月注册成立，并于2014年3月开始主要运营。该公司是一家临床阶段的生物制药公司，利用对抗病毒药物开发、药物化学、生物学、生物化学和病毒学的深刻理解，发现和开发新型口服候选产品，以治疗严重的病毒性疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.162254},{"month":2,"riseRate":0.5,"avgChangeRate":-0.030852},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.003624},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.147345},{"month":5,"riseRate":0.5,"avgChangeRate":0.039202},{"month":6,"riseRate":0.333333,"avgChangeRate":0.000002},{"month":7,"riseRate":0.833333,"avgChangeRate":0.068954},{"month":8,"riseRate":0.5,"avgChangeRate":0.021513},{"month":9,"riseRate":0.2,"avgChangeRate":-0.087115},{"month":10,"riseRate":0.6,"avgChangeRate":-0.088466},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.082616},{"month":12,"riseRate":0.833333,"avgChangeRate":0.089295}],"exchange":"NASDAQ","name":"Atea Pharmaceuticals, Inc.","nameEN":"Atea Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atea Pharmaceuticals, Inc.(AVIR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Atea Pharmaceuticals, Inc.(AVIR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Atea Pharmaceuticals, Inc.,AVIR,Atea Pharmaceuticals, Inc.股票,Atea Pharmaceuticals, Inc.股票老虎,Atea Pharmaceuticals, Inc.股票老虎国际,Atea Pharmaceuticals, Inc.行情,Atea Pharmaceuticals, Inc.股票行情,Atea Pharmaceuticals, Inc.股价,Atea Pharmaceuticals, Inc.股市,Atea Pharmaceuticals, Inc.股票价格,Atea Pharmaceuticals, Inc.股票交易,Atea Pharmaceuticals, Inc.股票购买,Atea Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atea Pharmaceuticals, Inc.(AVIR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Atea Pharmaceuticals, Inc.(AVIR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}